GRAIL (GRAL) Set to Release Earnings on Wednesday

GRAIL (NASDAQ:GRAL) will likely be announcing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect GRAIL to announce earnings of ($2.45) per share and revenue of $44.21 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, beating the consensus estimate of ($2.66) by $0.10. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. The company had revenue of $44.69 million during the quarter, compared to analysts’ expectations of $42.39 million. On average, analysts expect GRAIL to post ($10.07) EPS for the current fiscal year and ($10.80) EPS for the next fiscal year.

GRAIL Stock Performance

Shares of NASDAQ:GRAL traded down $0.37 during trading hours on Monday, reaching $143.06. The stock had a trading volume of 93,539 shares, compared to its average volume of 969,147. GRAIL has a 1 year low of $41.50 and a 1 year high of $166.48. The firm’s 50 day moving average is $112.02 and its 200-day moving average is $78.55. The stock has a market capitalization of $6.39 billion, a price-to-earnings ratio of -14.58 and a beta of 2.86.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Guggenheim increased their price objective on GRAIL from $75.00 to $155.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. TD Cowen raised their price objective on GRAIL from $88.00 to $180.00 and gave the company a “buy” rating in a research note on Tuesday, October 13th. Wall Street Zen raised GRAIL from a “sell” rating to a “hold” rating in a report on Sunday, September 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a research report on Thursday, October 15th. Finally, Mizuho boosted their target price on GRAIL from $65.00 to $100.00 and gave the stock a “neutral” rating in a research report on Friday, September 25th. Five research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $119.80.

Insider Transactions at GRAIL

In other news, CEO Joshua Ofman sold 20,000 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $136.85, for a total transaction of $2,737,000.00. Following the transaction, the chief executive officer directly owned 342,271 shares of the company’s stock, valued at approximately $46,839,786.35. The trade was a 5.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew Partridge sold 7,873 shares of the company’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $146.39, for a total transaction of $1,152,528.47. Following the completion of the transaction, the insider directly owned 155,865 shares of the company’s stock, valued at approximately $22,817,077.35. The trade was a 4.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 129,944 shares of company stock valued at $14,832,805 over the last quarter. Company insiders own 1.83% of the company’s stock.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a healthcare company focused on developing blood-based screening technologies for the early detection of cancer. Its principal product is Galleri, a multi-cancer early detection test designed to identify DNA patterns associated with multiple types of cancer from a single blood sample.

Galleri is intended for use alongside recommended cancer screenings and is available by prescription through qualified healthcare providers in the United States. The test is offered as a laboratory-developed test and has not been approved or cleared by the U.S.